CTAD taskforce: genetic therapies in Alzheimer's disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Alzheimer's disease and other dementias represent a growing global health challenge.
• Genetic approaches are emerging as a promising therapeutic avenue.
• Early-phase trials indicate potential efficacy for genetic therapies.

Purpose of the Study:

• To review preclinical studies and clinical trials of genetic therapies for Alzheimer's disease and dementias.
• To identify key lessons and challenges in the field of neurogenetic therapeutics.
• To foster collaboration through the first EU-US CTAD Task Force on genetic therapies.

Main Methods:

• Review of existing preclinical studies.
• Analysis of data from early-phase clinical trials.
• Discussion and synthesis of challenges and opportunities in neurogenetic therapy development.

Main Results:

• Promising results have emerged from early-phase trials of genetic therapies.
• Several unique challenges and opportunities in neurogenetic therapies were identified.
• The importance of interdisciplinary collaboration and patient involvement was highlighted.

Conclusions:

• Continued collaboration across disciplines is crucial for accelerating the development of neurogenetic therapeutics.
• Addressing challenges such as genetic manipulation, adverse events, monitoring, and therapy timing is essential.
• Patient involvement in trial design is vital for successful neurogenetic therapy development.